Showing 51-60 of 81 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21990/Therapeutics Update
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/theraputics-update/20510/New products and pharmacologic developmentsWardrobe
Malfunctionhttps://practicaldermatology.com/topics/practice-management/wardrobe-malfunction/20913/Top dermatologists share tips on dressing for success.Icotrokinra and the Oral Therapy Revolution
https://practicaldermatology.com/topics/psoriasis/icotrokinra-and-the-oral-therapy-revolution/60986/Icotrokinra is the only commercially available therapy that selectively blocks the receptor of IL-23 rather than the IL-23 cytokine.Next-Generation TYK2 Inhibitors in Psoriasis
https://practicaldermatology.com/topics/psoriasis/next-generation-tyk2-inhibitors-in-psoriasis/60985/Phase 3 clinical data and emerging therapeutic implications demonstrate the promise of zasocitinib and envudeucitinib.Medical Education and Technology: Intertwined like the Rod of Asclepius
https://practicaldermatology.com/columns/clinical-focus-1/medical-education-and-technology-intertwined-like-the-rod-of-asclepius/23453/Shedding Some Light on Hair Loss
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/shedding-some-light-on-hair-loss/23191/A look at the evolution of laser- and LED-assisted hair regrowth and the future of light therapy in the treatment of androgenetic alopeciaRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/23510/Smoothing Out Our Understanding of Moisturizers
https://practicaldermatology.com/topics/skin-cancer-photoprotection/smoothing-out-our-understanding-of-moisturizers/20688/New science and new approaches for dry skin.The HRQoL Impact of Psoriasis: Perspectives for Value-Based Reimbursement
https://practicaldermatology.com/topics/psoriasis/the-hrqol-impact-of-psoriasis-perspectives-for-value-based-reimbursement/20932/Understanding the psychological/social burden of psoriasis on patients is critical as new therapeutics position themselves for reimbursement in a crowded and increasingly undifferentiated field.